BRAF V600E 突变在结直肠癌（CRC）中是一个重要的生物标志物，约占所有结直肠癌病例的 10%。这一突变通常与肿瘤的侵袭性、预后不良以及对常规化疗的耐药性相关联[1]。研究显示，BRAF V600E 突变导致肿瘤细胞激活 MAPK ...

One target for such inhibition, the p38 mitogen-activated protein kinase (MAPK) signaling cascade, has a role in inflammation by mediating the cellular response to stress, pathogens, and cytokines.

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.

In cancer-associated cachexia, elevated TNF-α and IL-6 exacerbate muscle and fat loss by regulating multiple metabolic signaling pathways, which could be ameliorated by Z526's suppression of NF-κB ...

"Our findings represent a breakthrough in the treatment of HCM in children, particularly those suffering from severe forms of the disease due to genetic variants in the RAS/MAPK pathway," said ...